9 recruiting, 7 active not recruiting, 3 not yet recruiting, 3 unknown. 25 Phase 2, 4 Phase 1.
Follow Extensive-stage Small-cell Lung Cancer: new trials by email Literature Review of Extensive-stage Small-cell Lung Cancer trials Research Report on Extensive-stage Small-cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-10-12 | 2026-11-06 |
| A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer BL-M14D1, Atezolizumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 36 | 2026-07-09 | 2026-11-02 |
| Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Tafolecimab, Sintilimab (approved), Etoposide - Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2025-07-30 | 2026-09-15 |
| Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases Bevacizumab - Extensive-stage Small-cell Lung Cancer, Liver Metastases | Phase 2 | Recruiting | Kamya Sankar | 39 | 2024-08-11 | 2026-10-08 |
| Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide - Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Active not recruiting | BioNTech SE | 110 | 2024-08-05 | 2026-11-06 |
| Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC Tislelizumab, Etoposide, Carboplatin or Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Second Hospital of Shanxi Medical University | 40 | 2024-08-01 | 2026-04-24 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer BL-B01D1, PD-1 monoclonal antibody - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 66 | 2024-06-13 | 2026-07-23 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC Low-dose radiotherapy, Etoposide, Cisplatin - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 45 | 2024-04-18 | 2026-05-05 |
| MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer MGC018 - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Georgetown University | 9 | 2024-04-15 | 2026-06-25 |
| Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Baohui Han | 80 | 2024-04-01 | 2024-03-27 |
| A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. adebrelimab, famitinib, chemotherapy - Extensive-stage Small-cell Lung Cancer | Phase 2 | Not yet recruiting | Harbin Medical University | 40 | 2024-03-15 | 2024-03-12 |
| First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy Thoracic Radiotherapy - Extensive-stage Small-cell Lung Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 47 | 2023-12-01 | 2024-09-19 |
| Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC Thoracic Radiochemotherapy, durvalumab, Stereotactic radiotherapy of further tumor locations - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Universität des Saarlandes | 43 | 2023-10-06 | 2024-04-05 |
| Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer Association of lurbinectedin and durvalumab, Association of carboplatin and etoposide - Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma | Phase 2 | Withdrawn | Institut Bergonié | 2023-10-01 | 2024-06-05 | |
| Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC serplulimab, Cisplatin, Carboplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Sichuan University | 61 | 2023-03-07 | 2026-04-29 |
| Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC Surufatinib Durvalizumab EP/EC - Extensive-stage Small-cell Lung Cancer | Phase 2 | Unknown | Beijing Chest Hospital | 20 | 2022-12-01 | 2022-12-30 |
| Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) Ablative Radiation, Durvalumab, Etoposide - Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | University of Chicago | 49 | 2022-08-19 | 2026-03-04 |
| Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 2 | Not yet recruiting | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 58 | 2022-08-01 | 2022-08-05 |
| Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer QL1706, Carboplatin, Etoposide - Extensive-stage Small-cell Lung Cancer | Phase 2 | Completed | Qilu Pharmaceutical Co., Ltd. | 40 | 2022-04-18 | 2025-01-17 |
| Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Ifinatamab Deruxtecan (I-DXd) - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Daiichi Sankyo | 187 | 2022-03-09 | 2026-02-25 |
Showing 20 of 25. Sign in to see all of them.
Small Cell Lung Carcinoma (25) · Lung Neoplasms (4) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Neuroendocrine Tumors (1)
Bronchial Neoplasms (25) · Carcinoma, Bronchogenic (25) · Lung Diseases (25) · Neoplasms (25) · Neoplasms by Site (25) · Respiratory Tract Diseases (25) · Respiratory Tract Neoplasms (25) · Thoracic Neoplasms (25) · Lung Neoplasms (21) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1)
Etoposide (13) · Carboplatin (11) · Cisplatin (8) · durvalumab (7) · Radiotherapy (3) · Drug Therapy (2) · famitinib (2) · ADP Ribose Transferases (1) · Bevacizumab (1) · PM 01183 (1) · Paclitaxel (1) · Platinum (1) · Radiosurgery (1) · Topotecan (1) · atezolizumab (1)
Sichuan University (2) · 23andMe, Inc. (1) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Amgen (1) · Baohui Han (1) · Beijing Chest Hospital (1) · BioNTech SE (1) · Biokin (Shanghai) Biopharmaceutical Co., Ltd. (1) · Daiichi Sankyo (1) · Georgetown University (1) · Harbin Medical University (1) · Henan Cancer Hospital (1) · Institut Bergonié (1) · Jazz Pharmaceuticals (1) · Kamya Sankar (1)
China (12) · United States (8) · Australia (2) · Canada (2) · France (2) · Germany (2) · South Korea (2) · Japan (1) · Russia (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · United Kingdom (1)
You Lu, MD (3) · Caicun Zhou, PHD (1) · Christine Bestvina, MD (1) · Chul Kim, MD (1) · Eric Hau (1) · Gang Jin, Dr. (1) · Huaping S Yang, M.D (1) · Kamya Sankar, MD (1) · Lu Lu Su, MD (1) · Sagun Parakh (1) · Shu Jie Li, MM (1) · Shun Dong Cang, MD (1)
PMID 35526266, PMID 39185596, PMID 39651931, PMID 40623886, PMID 41086386
2025 (1)